Data analysis based on clinical data also showed that patients exhibiting elevated levels of CD83 in the context of mUC, mGC, NSCLC, CLL, and melanoma demonstrated heightened susceptibility to immune checkpoint inhibitors. The gene discussed is CD83; the disease is melanoma.